Critically Ill Patients with Coronavirus Disease 2019 in a Designated ICU: Clinical Features and Predictors for Mortality

References

• World Health Organization. Coronavirus disease 2019 (COVID-19): situation report—89. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200418-sitrep-89-covid-19.pdf?sfvrsn=3643dd38_2. Accessed 418, 2020.
   Google Scholar
• Liu X, Zhou H, Zhou Y, et al. Risk factors associated with disease severity and length of hospital stay in COVID-19 patients. J Infect. 2020;81(1):e95–e97. doi:10.1016/j.jinf.2020.04.00832305490
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5.31986264
   PubMed Web of Science ®Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi:10.1016/S2213-2600(20)30079-5.32105632
   PubMed Web of Science ®Google Scholar
• WHO. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected interim guidance 28 january 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf?sfvrsn=bc7da517_6&download=true7.http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf.
   Google Scholar
• Available from: http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf.
   Google Scholar
• Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet. 2019;394(10212):1949–1964. doi:10.1016/S0140-6736(19)32563-231777389
   PubMed Web of Science ®Google Scholar
• Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020;64(5):e00399–20. doi:10.1128/AAC.00399-2032152082
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. doi:10.1038/s41467-019-13940-631924756
   PubMed Web of Science ®Google Scholar
• Khalid M, Al Rabiah F, Khan B, Al Mobeireek A, Butt TS, Al Mutairy E. Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases. Antivir Ther. 2015;20(1):87–91. doi:10.3851/IMP279224831606
   PubMed Web of Science ®Google Scholar
• Tu H, Tu S, Gao S, Shao A, Sheng J. The epidemiological and clinical features of COVID-19 and lessons from this global infectious public health event. J Infect. 2020;81(1):1–9. doi:10.1016/j.jinf.2020.04.01132315723
   PubMed Web of Science ®Google Scholar
• Choi KW, Chau TN, Tsang O, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med. 2003;139(9):715–723. doi:10.7326/0003-4819-139-9-200311040-0000514597455
   PubMed Web of Science ®Google Scholar
• Ko JH, Park GE, Lee JY, et al. Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients. J Infect. 2016;73(5):468–475. doi:10.1016/j.jinf.2016.08.00527519621
   PubMed Web of Science ®Google Scholar
• Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus Spike receptor-binding domain complexed with receptor. Science. 2005;309(5742):1864–1868. doi:10.1126/science.111648016166518
   PubMed Web of Science ®Google Scholar
• Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J Infect. 2020;81(1):e1–e5. doi:10.1016/j.jinf.2020.03.00232171872
   PubMed Web of Science ®Google Scholar
• Xie X, Chen J, Wang X, Zhang F, Liu Y. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci. 2006;78(19):2166‐2171. doi:10.1016/j.lfs.2005.09.038
   Web of Science ®Google Scholar
• Soro-Paavonen A, Gordin D, Forsblom C, et al. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens. 2012;30(2):375‐383. doi:10.1097/HJH.0b013e32834f04b6
   Web of Science ®Google Scholar
• Jia H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock. 2016;46(3):239–248. doi:10.1097/SHK.000000000000063327082314
   PubMed Web of Science ®Google Scholar
• Busse LW, Chow JH, McCurdy MT, Khanna AK. COVID-19 and the RAAS-a potential role for angiotensin II? Crit Care. 2020;24(1):136. doi:10.1186/s13054-020-02862-132264922
   PubMed Web of Science ®Google Scholar
• Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523. doi:10.1016/S0140-6736(20)30154-931986261
   PubMed Web of Science ®Google Scholar
• Fan Y, Zhao K, Shi ZL, Zhou P. Bat coronaviruses in China. Viruses. 2019;11(3):210. doi:10.3390/v11030210
   PubMed Web of Science ®Google Scholar
• Nicin L, Abplanalp WT, Mellentin H, et al. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. Eur Heart J. 2020;41(19):1804–1806. doi:10.1093/eurheartj/ehaa31132293672
   PubMed Web of Science ®Google Scholar
• Yu CM, Wong RS, Wu EB, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006;82(964):140‐144. doi:10.1136/pgmj.2005.037515
   Web of Science ®Google Scholar
• Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;31(5):1003–1008. doi:10.1111/jce.1447932270559
   PubMed Web of Science ®Google Scholar
• Saad M, Omrani AS, Baig K, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single‐center experience in Saudi Arabia. Int J Infect Dis. 2014;29:301‐306. doi:10.1016/j.ijid.2014.09.003
   Web of Science ®Google Scholar
• Basile-Filho A, Lago AF, Menegueti MG, et al. The use of APACHE II, SOFA, SAPS 3, C-reactive protein/albumin ratio, and lactate to predict mortality of surgical critically ill patients: a retrospective cohort study. Medicine (Baltimore). 2019;98(26):e16204. doi:10.1097/MD.000000000001620431261567
   PubMed Web of Science ®Google Scholar
• Innocenti F, Tozzi C, Donnini C, et al. SOFA score in septic patients: incremental prognostic value over age, comorbidities, and parameters of sepsis severity. Intern Emerg Med. 2018;13(3):405–412. doi:10.1007/s11739-017-1629-528188577
   PubMed Web of Science ®Google Scholar
• García-Gigorro R, Sáez-de la Fuente I, Marín Mateos H, Andrés-Esteban EM, Sanchez-Izquierdo JA, Montejo-González JC. Utility of SOFA and Δ-SOFA scores for predicting outcome in critically ill patients from the emergency department. Eur J Emerg Med. 2018;25(6):387–393. doi:10.1097/MEJ.000000000000047228509709
   PubMed Web of Science ®Google Scholar